Akebia Therapeutics is followed by the analysts listed above. View Akebia Therapeutics, Inc. AKBA investment & stock information. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Its products include Auryxia and Vadadustat. Please log in to your account or sign up in order to add this asset to your watchlist. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. What is AKBA's earnings growth forecast for 2020-2022? Find the latest Earnings Report Date for Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Their forecasts range from $3.00 to $18.00. The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. Do Not Sell My Information. Akebia Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, Jason Amello, Maxine Gowen, Michel Dahan, and Nicole R Hadas. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Akebia Therapeutics's earnings in 2020 is -$390,940,000.On average, 4 Wall Street analysts forecast AKBA's earnings for 2020 to be $-256,179,865, with the lowest AKBA earnings forecast at $-266,570,377, and the highest AKBA earnings forecast at $-245,072,766. Similar to Selecta, Akebia Therapeutics Inc. ( AKBA Stock Report ) also fell earlier this year after bad news. (NASDAQ: AKBA) Akebia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of -1.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 12.63%. View which stocks have been most impacted by COVID-19. View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240.2m in 2021, implying a stressful 22% … © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. During the day the stock fluctuated 10.87% from a day low at $2.30 to a day high of $2.55. Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021. What is AKBA's revenue growth forecast for 2020-2022? © American Consumer News, LLC dba MarketBeat® 2010-2020. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Out of 6 analysts, 4 (66.67%) are recommending AKBA as a Strong Buy, 0 (0%) are recommending AKBA as a Buy, 2 (33.33%) are recommending AKBA as a Hold, 0 (0%) are recommending AKBA as a Sell, and 0 (0%) are recommending AKBA as a Strong Sell. It's shaping up to be a tough period for Akebia Therapeutics, Inc. (NASDAQ:AKBA), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock.Statutory earnings fell substantially short of expectations, with revenues of US$60m missing forecasts by 33%. 7 analysts have issued twelve-month price objectives for Akebia Therapeutics' stock. What is AKBA's Earnings Per Share (EPS) forecast for 2020-2022? It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 (NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of -10.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.86%. Short-term (time horizon: 2 weeks) AKEBIA THERAPEUTICS INC share price prediction for 2020-09 … Learn about financial terms, types of investments, trading strategies and more. Export data to Excel for your own analysis. According to analysts' consensus price target of $10.29, Akebia Therapeutics has a forecasted upside of 210.7% from its current price of $3.31. Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The official website for Akebia Therapeutics is www.akebia.com. Receive a free world-class investing education from MarketBeat. Hi everyone! Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA.". View institutional ownership trends for Akebia Therapeutics. Thanks a million! The average price target is $6.71 with a high forecast of $10.00 and a low forecast of $3.00.The average price target represents a 103.33% increase from the last price of $3.30. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.25. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. This suggests a possible upside of 210.7% from the stock's current price. The P/E ratio of Akebia Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. AKBA stock … High institutional ownership can be a signal of strong market trust in this company. Akebia Therapeutics has a market capitalization of $478.42 million and generates $335 million in revenue each year. Learn everything you need to know about successful options trading with this three-part video course. Analysts forecast that Akebia Therapeutics will post -1.5 earnings per share for the current year. View our earnings forecast for Akebia Therapeutics. One share of AKBA stock can currently be purchased for approximately $3.31. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. See Akebia Therapeutics, Inc. (AKBA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. In comparing Akebia Therapeutics, Inc. (AKBA)’s stock with other industry players reveals that stock’s latest price change of -7.96% and that of -22.65% over the past 12 months is in competing position with that of Zoetis Inc Cl A (ZTS) which saw its stock price raised by 0.93% in the recent trading and went through an increase of 31.24% in past 12-month trading. In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%.During that period the price should oscillate between -7.35% and +13.91%.. Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. View insider buying and selling activity for Akebia Therapeutics. You may vote once every thirty days. Since then, AKBA stock has decreased by 52.3% and is now trading at $3.31. The firm has a Buy on the stock with an SELB stock forecast of $6. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Their average twelve-month price target is $10.29, predicting that the stock has a possible upside of 203.41%. Despite being -2.12% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 19 when the AKBA stock price touched $3.96-6 or saw a rise of 6.57%. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. AKBA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Nantahala Capital Management LLC, Charles Schwab Investment Management Inc., Cubist Systematic Strategies LLC, Sei Investments Co., Skandinaviska Enskilda Banken AB publ , Quantitative Systematic Strategies LLC, and Massachusetts Financial Services Co. MA. Top institutional shareholders include State Street Corp (10.70%), BlackRock Inc. (8.19%), Nantahala Capital Management LLC (3.98%), Morgan Stanley (0.83%), Squarepoint Ops LLC (0.71%) and Charles Schwab Investment Management Inc. (0.65%). According to 6 Wall Street analysts that have issued a 1 year AKBA price target, the average AKBA price target is $10.17, with the highest AKBA stock price forecast at $18.00 and the lowest AKBA stock price forecast at $3.00. Akebia Therapeutics (AKBA) stock price prediction is 1.050727 USD. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. I saw some exciting stuff about Akebia Therapeutics for example I saw a few different stock forecasts giving it a forecast of $6 or even more (currently trades at $2.22). Penny Stocks To Buy [according to HC Wainwright]: Akebia Therapeutics Inc. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. View insider buying and selling activity for Akebia Therapeutics. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. View analysts' price targets for Akebia Therapeutics. Are Disney Layoffs a Signal to Lay off the Stock? AKBA stock forecast Our latest prediction for Akebia Therapeutics, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$.. The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts … Based on 8 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings. See what's happening in the market right now with MarketBeat's real-time news feed. (Add your “underperform” vote.). View Akebia Therapeutics' earnings history. What this means: InvestorsObserver gives Akebia Therapeutics Inc (AKBA) an overall rank of 34, which is below average. View our full suite of financial calendars and market data tables, all for free. All rights reserved. Only 2.55% of the stock of Akebia Therapeutics is held by insiders. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. Akebia Therapeutics does not currently pay a dividend. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]. In the medium term (3months), AKBA's stock price should outperform the market by 7.18%. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings results on Tuesday, November, 10th. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Close price at the end of the last trading day (Thursday, 5th Nov 2020) of the AKBA stock was $2.49. Akebia Therapeutics's revenue in 2020 is $308,163,000.On average, 4 Wall Street analysts forecast AKBA's revenue for 2020 to be $40,848,757,295, with the lowest AKBA revenue forecast at $40,584,623,314, and the highest AKBA revenue forecast at $41,188,132,915. Akebia reported that patients who took Vadadustat were shown to have increased heart risks, especially when compared to a similar treatment made by rival Amgen (NASDAQ:AMGN). Researching Akebia Therapeutics (NASDAQ:AKBA) stock? How Should You Play At Home Group (NYSE: HOME) Ahead of Earnings? Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Akebia Therapeutics has received a consensus rating of Buy. What is AKBA's forecast return on equity (ROE) for 2020-2023? Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. View analyst ratings for Akebia Therapeutics or view MarketBeat's top 5 stock picks. Akebia Therapeutics has received 388 “outperform” votes. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. As can be gleaned from the statistics, the company’s share value dive -76.3% over the past 6 months, a 11.44% in annual growth rate that is considerably lower than the industry average of 15.4%. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. AKEBIA THERAPEUTICS INC stock price forecast for further price development up to 240.68% (time horizon: 1 day) and price target of 9.27 USD. The Akebia Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 40, which is below average. In 2022, AKBA is forecast to generate $-62,343,072 in earnings, with the lowest earnings forecast at $-110,354,403 and the highest earnings forecast at $2,866,348. Get daily stock ideas top-performing Wall Street analysts. What is AKBA's forecast return on assets (ROA) for 2020-2023? Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. Akebia Therapeutics, Inc. (AKBA) estimates and forecasts Data shows that the Akebia Therapeutics, Inc. share is not performing relatively much better than most of its peers within the same industry.